DOCS vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Doximity exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and an exceptionally clean balance sheet characterized by near-zero debt. Despite elite gross margins (89.75%) and strong liquidity, the company is experiencing a severe valuation correction with a 1-year price decline of 57.4% and negative earnings growth (-16.20%). The current price of $24.01 trades at a significant premium to its Graham Number ($11.91) and Intrinsic Value ($8.33), indicating a disconnect between fundamental defensive value and market pricing. While analyst targets remain bullish, the combination of negative earnings momentum and bearish insider activity suggests caution.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
DOCS vs MRK: Head-to-Head Comparison
This page compares Doximity, Inc. (DOCS) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.